Randomized phase-3 study: tarlatamab, a DLL3-targeting bispecific t-cell engager (BiTE), compared to standard-of-care in relapsed small cell lung cancer (DeLLphi-304)
Authors
Rodriguez, L. P. A.Felip, E.
Ahn, M. J.
Blackhall, Fiona H
Borghaei, H.
Cho, B. C.
Johnson, M. L.
Ramalingam, S. S.
Reck, M.
Jiang, T.
Ju, C. H.
Minocha, M.
Mukherjee, S.
Suri, G.
Recondo, G.
Martinezi, P.
Affiliation
The Christie NHS Foundation Trust, Division of Cancer Sciences, Manchester, United KingdomIssue Date
2024